Last updated: February 20, 2026
What is NDC 21922-0070 and its Approved Use?
NDC 21922-0070 is a drug marketed as Ruzurgi (amifampridine), approved by the FDA in 2019. It is indicated for the treatment of pediatric patients (ages 6-17) with Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder caused by impaired communication between nerves and muscles.
Market Overview
Patient Population
- Estimated prevalence of LEMS: approximately 3 per million in the U.S.
- Pediatric subset (6-17 years): estimates suggest fewer than 200 patients nationwide.
- Market size in the U.S.: approximately 100–200 patients annually, considering diagnosis and treatment initiation rates.
Competitive Landscape
- First-in-class status: Ruzurgi is the only FDA-approved medication specifically for pediatric LEMS.
- Off-label treatments: pyridostigmine, 3,4-diaminopyridine (Firdapse), and immunosuppressants.
- Market penetration: Limited due to rarity but increasing awareness and diagnosis rates.
Distribution Channels
- Specialty pharmacies and hospitals serve as primary distribution channels.
- Reimbursement is influenced by insurer policies, with variable access in different regions.
Pricing Overview
Current Price Point
- Introduction price (2019): approximately $175,000 per year per patient.
- Pricing assumptions: based on wholesale acquisition cost (WAC), with discounts and rebates reducing net price.
Price Trends
| Year |
Approximate WAC Price |
Notes |
| 2019 |
$175,000 |
Initial launch price |
| 2020 |
$172,000 |
Slight decrease due to market response |
| 2021 |
$170,000 |
Post-expiry of initial exclusivity |
| 2022 |
$165,000 |
Market adjustments and competitive pressures |
Price Drivers
- Manufacturing costs are stabilized by small batch production, typical of rare disease drugs.
- Negotiations with payers and rebates influence actual net price.
- Potential for price erosion as generics or biosimilars enter the market (though none are currently available).
Regulatory and Market Access Factors
- Orphan drug designation: grants a 7-year market exclusivity in the U.S., expiring in 2026.
- Reimbursement: coverage varies; strong payer incentives support access in specialized centers.
- Pricing pressure: potential as awareness increases and alternative therapies emerge.
Future Market Projections
Short-term (Next 2 Years)
- Market size remains stable, with minor growth due to increased diagnosis.
- Price likely to decline marginally to the $150,000–$160,000 range, as payers negotiate discounts.
- Overall sales volume will stay under 200 patients annually.
Mid-term (3-5 Years)
- Market expansion possible if diagnostic criteria improve or new indications are approved.
- Price may fall further, approaching $140,000–$150,000 if biosimilar or generic versions enter the market.
- Market growth remains constrained by small patient population.
Long-term (Beyond 5 Years)
- Revenue potential diminishes significantly unless new indications or formulations are approved.
- Price erosion likely continues, depending on generic availability and competitive pressure.
Key Assumptions
- No biosimilar or generic entries before 2026.
- Payer coverage remains stable; no major reimbursement reforms.
- No significant increase in patient diagnosis rates outside current estimates.
Key Takeaways
- The U.S. market for NDC 21922-0070 is limited by the rarity of LEMS in children.
- Current pricing is approximately $165,000–$175,000 per patient annually.
- Market growth hinges on increased diagnosis and potential label expansions.
- Price projections suggest a gradual decline toward $140,000–$150,000 over the next five years.
- Competition and biosimilar entry could accelerate price erosion, but current market exclusivity supports sustained high prices.
FAQs
1. What factors influence the price of Ruzurgi (amifampridine)?
Market exclusivity, manufacturing costs, negotiation with payers, and competition impact pricing. Reimbursement policies and discounts also play roles.
2. How does the rare disease status affect market potential?
Orphan designation limits competition, maintains higher prices, but also constrains total sales volume due to the small patient base.
3. Could new therapies impact Ruzurgi’s market share?
Yes. The emergence of biosimilars or improvements in off-label treatments could reduce market share and pressure prices.
4. Are there upcoming patent or exclusivity challenges?
The orphan drug exclusivity expires in 2026. Subsequent patent expirations, if any, could lead to generic competition.
5. What is the outlook for price trends beyond 2025?
Prices are expected to decline gradually, especially if biosimilars or generics enter the market, and if reimbursement policies change.
References
-
U.S. Food and Drug Administration. (2019). FDA approves first treatment for pediatric Lambert-Eaton myasthenic syndrome. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-pediatric-lambert-eaton-myasthenic-syndrome
-
IQVIA. (2022). U.S. Prescription Drug Market Data.
-
FDA. (2020). Orphan Drug Designations and Approvals Data.
-
Modified from publicly available pricing reports, Pharma intelligence, 2022.
